Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) — Working Capital to Net Assets Ratio
Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) has a Working Capital to Net Assets ratio of 74.9% as of June 2025. Working capital of CN¥1.44 Billion (current assets of CN¥1.59 Billion minus current liabilities of CN¥153.70 Million) is measured against net assets of CN¥1.92 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 301258 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Suzhou Fushilai Pharmaceutical Co. Ltd. Working Capital to Net Assets (2019–2024)
This chart shows how Suzhou Fushilai Pharmaceutical Co. Ltd.'s Working Capital to Net Assets ratio has evolved across 6 annual periods from 2019 to 2024. As of June 2025, the ratio stands at 74.9%, reflecting working capital of CN¥1.44 Billion against net assets of CN¥1.92 Billion CNY. See 301258 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Suzhou Fushilai Pharmaceutical Co. Ltd. (2019–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Suzhou Fushilai Pharmaceutical Co. Ltd. from 2019 to 2024, covering 6 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 301258 company net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 77.7% | CN¥1.47 Billion | CN¥1.89 Billion | CN¥1.61 Billion | CN¥145.25 Million | ▼ -1.3 pp |
| 2023 | 79.0% | CN¥1.54 Billion | CN¥1.95 Billion | CN¥1.65 Billion | CN¥112.10 Million | ▼ -0.5 pp |
| 2022 | 79.5% | CN¥1.50 Billion | CN¥1.89 Billion | CN¥1.65 Billion | CN¥149.91 Million | ▲ +33.3 pp |
| 2021 | 46.2% | CN¥343.43 Million | CN¥742.84 Million | CN¥516.60 Million | CN¥173.17 Million | ▲ +4.2 pp |
| 2020 | 42.1% | CN¥262.00 Million | CN¥622.64 Million | CN¥372.98 Million | CN¥110.98 Million | ▼ -1.9 pp |
| 2019 | 44.0% | CN¥256.18 Million | CN¥581.96 Million | CN¥380.88 Million | CN¥124.70 Million | — |